Pharmaco-economical Study in Kidney Transplantation
Completed
- Conditions
- Renal Transplant
- Registration Number
- NCT01989832
- Lead Sponsor
- University Hospital, Limoges
- Brief Summary
The prevalence of renal acute rejection in transplantation is reduced thanks to the optimized use of immunosuppressive drugs. However, graft survival at ten years has not improved since then; this may be explained in part by the toxicity of these drugs, viral infections, and other comorbidities (diabetes, cardiovascular diseases ...).
According to transplant center, strategies for the combination of immunosuppressive drugs are different, and probably involve a difference in the global cost of patient management. There is no recommendation in France to establish similar practices.
EPHEGREN is an observational, prospective, multicentric, pharmacoeconomic study for the renal transplant patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 570
Inclusion Criteria
- Patients in the first month of renal graft, or patients already included in an other epidemiological French study (EPIGREN) in the 0-6 month period
- Men of women aged more than 18 years
- Patients able to exercise in writing their informed and free consent to participate to the biological collection
- Patients not opposing to collect their medical data
- Patients registered with a social security system
- Patients able to complete the questionnaires
Exclusion Criteria
- Patients aged less than 18 years and patients under guardianship
- Patients with a follow-up at another center other than those part of the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Death 4 years
- Secondary Outcome Measures
Name Time Method to examine nature, dose and exposure in immunosuppresseurs. 4 years